Identification of an NF1 Microdeletion with Optical Genome Mapping

被引:3
|
作者
Buki, Gergely [1 ]
Beko, Anna [2 ]
Bodor, Csaba [2 ]
Urban, Peter [3 ]
Nemeth, Krisztina [4 ]
Hadzsiev, Kinga [1 ]
Fekete, Gyoergy [4 ]
Kehrer-Sawatzki, Hildegard [5 ]
Bene, Judit [1 ]
机构
[1] Univ Pecs, Clin Ctr, Med Sch, Dept Med Genet, H-7624 Pecs, Hungary
[2] Semmelweis Univ, Dept Pathol & Expt Canc Res, HCEMM SE Mol Oncohematol Res Grp, H-1085 Budapest, Hungary
[3] Univ Pecs, Szentagotha Res Ctr, Bioinformat Res Grp, Genom & Bioinformat Core Facil, H-7624 Pecs, Hungary
[4] Semmelweis Univ, Fac Med, Pediat Ctr, Tuzolto St Dept, H-1094 Budapest, Hungary
[5] Univ Ulm, Inst Human Genet, D-89081 Ulm, Germany
关键词
optical genome mapping; OGM; NF1; microdeletion; structural variation; copy number variation; gene; GENOTYPE-PHENOTYPE CORRELATION; NEUROFIBROMATOSIS; GENE; TYPE-1; EXPRESSION; MUTATIONS;
D O I
10.3390/ijms241713580
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Neurofibromatosis type 1 (NF1) is a clinically heterogeneous neurocutaneous disorder inherited in autosomal dominant manner. Approximately 5-10% of the cases are caused by NF1 microdeletions involving the NF1 gene and its flanking regions. Microdeletions, which lead to more severe clinical manifestations, can be subclassified into four different types (type 1, 2, 3 and atypical) according to their size, the genomic location of the breakpoints and the number of genes included within the deletion. Besides the prominent hallmarks of NF1, patients with NF1 microdeletions frequently exhibit specific additional clinical manifestations like dysmorphic facial features, macrocephaly, overgrowth, global developmental delay, cognitive disability and an increased risk of malignancies. It is important to identify the genes co-deleted with NF1, because they are likely to have an effect on the clinical manifestation. Multiplex ligation-dependent probe amplification (MLPA) and microarray analysis are the primary techniques for the investigation of NF1 microdeletions. However, based on previous research, optical genome mapping (OGM) could also serve as an alternative method to identify copy number variations (CNVs). Here, we present a case with NF1 microdeletion identified by means of OGM and demonstrate that this novel technology is a suitable tool for the identification and classification of the NF1 microdeletions.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Ketotifen Suppression of NF1 Neurofibroma Growth Over 30 Years
    Riccardi, Vincent M.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2015, 167 (07) : 1570 - 1577
  • [22] NF1 Exon 22 Analysis of Individuals With the Clinical Diagnosis of Neurofibromatosis Type 1
    Muram-Zborovski, Talia M.
    Vaughn, Cecily P.
    Viskochil, David H.
    Hanson, Heather
    Mao, Rong
    Stevenson, David A.
    AMERICAN JOURNAL OF MEDICAL GENETICS PART A, 2010, 152A (08) : 1973 - 1978
  • [23] Identification and characterization of NF1 splicing mutations in Korean patients with neurofibromatosis type 1
    Jang, Mi-Ae
    Kim, Young-Eun
    Kim, Sun Kyung
    Lee, Myoung-Keun
    Kim, Jong-Won
    Ki, Chang-Seok
    JOURNAL OF HUMAN GENETICS, 2016, 61 (08) : 705 - 709
  • [24] The NF1 microdeletion syndrome: early genetic diagnosis facilitates the management of a clinically defined disease
    Kehrer-Sawatzki, Hildegard
    Baezner, Ute
    Kraemer, Johannes
    Lewerenz, Jan
    Pfeiffer, Christiane
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2022, 20 (03): : 273 - 277
  • [25] The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma
    Berry, Diana
    Moldoveanu, Dan
    Rajkumar, Shivshankari
    Lajoie, Mathieu
    Lin, Tiffany
    Tchelougou, Damehan
    Sakthivel, Samridhi
    Sharon, Itai
    Bernard, Antoine
    Pelletier, Sandy
    Ripstein, Yael
    Spatz, Alan
    Miller, Wilson H.
    Jamal, Rahima
    Lapointe, Rejean
    Mes-Masson, Anne-Marie
    Petrecca, Kevin
    Meguerditchian, Ari-Nareg
    Richardson, Keith
    Wang, Beatrice
    Chergui, May
    Guiot, Marie-Christine
    Watters, Kevin
    Stagg, John
    Schmeing, T. Martin
    Rodier, Francis
    Turcotte, Simon
    Mihalcioiu, Catalin
    Meterissian, Sarkis
    Watson, Ian R.
    CELL REPORTS, 2025, 44 (03):
  • [26] A search for evidence of somatic mutations in the NF1 gene
    John, AM
    Ruggieri, M
    Ferner, R
    Upadhyaya, M
    JOURNAL OF MEDICAL GENETICS, 2000, 37 (01) : 44 - 49
  • [27] Neurofibromin (Nf1) is required for skeletal muscle development
    Kossler, Nadine
    Stricker, Sigmar
    Roedelsperger, Christian
    Robinson, Peter N.
    Kim, Johnny
    Dietrich, Carola
    Osswald, Monika
    Kuehnisch, Jirko
    Stevenson, David A.
    Braun, Thomas
    Mundlos, Stefan
    Kolanczyk, Mateusz
    HUMAN MOLECULAR GENETICS, 2011, 20 (14) : 2697 - 2709
  • [28] Identification of NF1 Frameshift Variants in Two Chinese Families With Neurofibromatosis Type 1 and Early-Onset Hypertension
    Lu, Yi-Ting
    Zhang, Di
    Liu, Xin-Chang
    Zhang, Qiong-Yu
    Dong, Xue-Qi
    Fan, Peng
    Xiao, Yan
    Zhou, Xian-Liang
    FRONTIERS IN PEDIATRICS, 2021, 9
  • [29] Multi-Omics Profiling for NF1 Target Discovery in Neurofibromin (NF1) Deficient Cells
    Carnes, Rachel M.
    Mobley, James A.
    Crossman, David K.
    Liu, Hui
    Korf, Bruce R.
    Kesterson, Robert A.
    Wallis, Deeann
    PROTEOMICS, 2019, 19 (11)
  • [30] NF1 patient missense variants predict a role for ATM in modifying neurofibroma initiation
    Yu, Yanan
    Choi, Kwangmin
    Wu, Jianqiang
    Andreassen, Paul R.
    Dexheimer, Phillip J.
    Keddache, Mehdi
    Brems, Hilde
    Spinner, Robert J.
    Cancelas, Jose A.
    Martin, Lisa J.
    Wallace, Margaret R.
    Legius, Eric
    Vogel, Kristine S.
    Ratner, Nancy
    ACTA NEUROPATHOLOGICA, 2020, 139 (01) : 157 - 174